CN105671046B - The siRNA of swine fever virus resistant infection and its application - Google Patents
The siRNA of swine fever virus resistant infection and its application Download PDFInfo
- Publication number
- CN105671046B CN105671046B CN201610121446.9A CN201610121446A CN105671046B CN 105671046 B CN105671046 B CN 105671046B CN 201610121446 A CN201610121446 A CN 201610121446A CN 105671046 B CN105671046 B CN 105671046B
- Authority
- CN
- China
- Prior art keywords
- swine fever
- sirna
- fever virus
- pro
- fluc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses the siRNA of swine fever virus resistant infection and its applications, belong to the identification and its application field of swine fever virus resistant siRNA.The present invention discloses targeting swine fever virus genome N respectively firstpro, P7, NS5A and NS5B gene swine fever virus resistant infection siRNA, nucleotide sequence is respectively shown in SEQ ID NO.1-12.It is respectively shown in SEQ ID NO.1, SEQ ID NO.7 or SEQ ID NO.12 that the present invention, which is further filtered out using the recombination swine fever virus of building to swine fever virus interference or the strongest siRNA of inhibitory activity, nucleotide sequence,.The invention also discloses the expression vector of the siRNA containing swine fever virus resistant infection and its applications.The siRNA of swine fever virus resistant infection of the present invention is strong to swine fever virus inhibitory activity, has the potentiality of the drug or reagent that are prepared into prevention or treatment swine fever.
Description
It is " on June 9th, 2014 " that the application, which is application No. is " 201410252667.0 ", the applying date, entitled " anti-
The divisional application of the siRNA of swine fever virus infection and its application ".
Technical field
The present invention relates to the swine fever virus resistant infection of swine fever virus resistant siRNA, more particularly to targeting swine fever virus genome
SiRNA, the invention further relates to targeting swine fever virus genome the siRNA with swine fever virus resistant infection activity making
The standby drug for preventing or treating swine fever or the application in reagent, belong to the identification and its application field of swine fever virus resistant siRNA.
Background technique
Swine fever (classical swine fever, CSF) is by swine fever virus (classical swine fever
Virus, CSFV) caused by a kind of contact, lethal infectious diseases, with high fever and bleeding for its characteristic feature, disease incidence and dead
It is high to die rate, being classified as by World Organization for Animal Health (OIE) must notifiable animal epidemic.
Swine fever virus (CSFV) is the member of flaviviridae (Flaviviridae) pestivirus (Pestivirus), is single
Stock normal chain linear rna molecule.CSFV Genome Size is 12.3kb, and both ends are respectively 5 ' end non-translational region (untranslated
Region, UTR) and 3 ' end UTR, intermediate includes a big open reading frame (Open reading frame, ORF), wherein
ORF encodes a polyprotein being made of 3898 amino acid residues.The polyprotein in the host cell of virus infection,
By host or the hydrolysis of the distinctive protease of virus, cleavable is 11 kinds of virus specified proteins, including 4 kinds of virus structures
Albumen (C, Erns, E1 and E2) and 7 kinds of non-structural protein (Npro, P7, NS2-3, NS4A, NS4B, NS5A and NS5B) (Moennig,
V.,2000.Introduction to classical swine fever:virus,disease and control
policy.Vet.Microbiol.73,93–102.)。
It is one of viral infection resisting most efficient method that RNA, which interferes (RNA interference, RNAi),.Using RNAi skill
Art can reduce the quantity of viral RNA, the expression of blocking virus albumen and the duplication for inhibiting virus etc., this technology is a variety of
In the gene therapy research of disease, huge potentiality and unique effect have been played.It is existing studies have shown that targeting hog cholera
Malicious Npro, NS3, NS4A and NS5B gene siRNA can inhibit the duplication of CSFV (Xu, X., Guo, H., Xiao, C., Zha,
Y.,Shi,Z.,Xia,X.,Tu,C.,2008.In vitro inhibition of classical swine fever
virus replication by siRNAs targeting Npro and NS5B genes.Antiviral Res.78,
188–193；Li,J.,Dai,Y.,Liu,S.,Guo,H.,Wang,T.,Ouyang,H.,Tu,C.,2011.In vitro
inhibition of CSFV replication by multiple siRNA expression.Antiviral Res.91,
209–216.)。
CSFV P7 is II class ionophorous protein, is played a crucial role in the life cycle of pestivirus, and with
Pathogenic related (Gladue, D.P., Holinka, L.G., Largo, E., Sainz, I.F., Carrillo, C., the O' of virus
Donnell,V.,Baker-Branstetter,R.,Lu,Z.,Ambroggio,X.,Risatti,G.R.,Nieva,J.L.,
Borca,M.V.,2012.Classical swine fever virus p7protein is a viroporin involved
in virulence in swine.J.Virol.86,6778–6791.).NS5A knows it in the exact function of CSFV life cycle
It is very few, it there is no the report of the swine fever virus resistant siRNA of targeting CSFV P7 and NS5A gene so far.
Summary of the invention
The technical problem to be solved in the present invention is to provide target swine fever virus genome N respectivelypro, P7, NS5A and NS5B base
The siRNA with swine fever virus resistant infection activity of cause, these siRNA have applied to the drug or examination for preventing or treating swine fever
The potentiality of agent, realization effectively prevent swine fever.
The technical problem to be solved by the present invention is to what is be achieved through the following technical solutions:
The present invention is according to swine fever virus genome NproThe coded sequence of gene, design targeting swine fever virus genome NproBase
The swine fever virus resistant siRNA of cause, nucleotides sequence are classified as shown in SEQ ID NO.1-3.
Coded sequence of the present invention according to swine fever virus genome P7 gene, design targeting swine fever virus genome P7 gene
Swine fever virus resistant siRNA, nucleotides sequence is classified as shown in SEQ ID NO.4-6.
Coded sequence of the present invention according to swine fever virus genome NS5A gene, design targeting swine fever virus genome NS5A
The swine fever virus resistant siRNA of gene, nucleotides sequence are classified as shown in SEQ ID NO.7-9.
Coded sequence of the present invention according to swine fever virus genome NS5B gene, design targeting swine fever virus genome NS5B
The swine fever virus resistant siRNA of gene, nucleotides sequence are classified as shown in SEQ ID NO.10-12.
The present invention is in order to identify the activity that whether these designed siRNA there is swine fever virus resistant to infect, structure of the present invention
The recombination swine fever virus CSFV-N of expression firefly luciferase gene is builtproFluc, the present invention is by swine fever recombinant virus
CSFV-NproThe mechanism that Fluc submits patent to approve carries out preservation, microbial preservation number are as follows: CGMCC No.9058；Classification
Name are as follows: express the recombination swine fever virus of firefly luciferase gene.Depositary institution: Chinese microorganism strain preservation management committee
Member can common micro-organisms center；The preservation time is on 04 11st, 2014；Preservation address: BeiJing, China, North Star West Road, Chaoyang District 1
Number institute 3, Institute of Microorganism, Academia Sinica.The present invention utilizes constructed expression firefly luciferase (Fluc) gene
Recombination swine fever virus assessment targeting swine fever virus genome Npro, P7, NS5A and NS5B gene 12 swine fever virus resistants
SiRNA molecule, testing result confirmation, siNpro- 108 (SEQ ID NO.1), siNS5A-239 (SEQ ID NO.7) and
SiNS5B-1234 (SEQ ID NO.12) is the interference or the strongest siRNA molecule of inhibitory activity to swine fever virus.
Wherein, the present invention provides 1 targeting CSFV genome NproGene has the active siRNA of swine fever virus resistant,
It is stronger to the interference of swine fever virus or inhibitory activity, and nucleotides sequence is classified as shown in SEQ ID NO.1.The present invention also provides
Utilize recombination swine fever virus CSFV-NproThe swine fever virus resistant siRNA for 1 targeting CSFV genome P7 gene that Fluc is filtered out,
There is strong interference effect to swine fever virus, nucleotides sequence is classified as shown in SEQ ID NO.4；The siRNA is of the invention first
The swine fever virus resistant siRNA of secondary disclosed targeting CSFV genome P7 gene.
The present invention utilizes CSFV-N simultaneouslyproFluc and its Shimen plants of parental virus have evaluated the targeting four that screening obtains
The interference performance of kind of gene by by force to 4 weak siRNA molecules various concentration antiviral effect.The swine fever virus resistant
SiRNA is siNpro- 108, siNS5B-1234, siNS5A-734 and siP7-55 target the N of swine fever virus genome respectivelypro、
NS5B, NS5A and P7 gene, nucleotide sequence are respectively SEQ ID NO.1, SEQ ID NO.12, SEQ ID NO.9 or SEQ
Shown in ID NO.4.
The present invention analyzes above-mentioned swine fever virus resistant siRNA in the antiviral of various concentration (50nm, 100nm and 150nm)
Effect.The result shows that 4 kinds of siRNA have significant inhibiting effect to swine fever virus in 50nm, 100nm and 150nm.It is right
In the cell that the siScr of 150nM is handled, CSFV-NproThe Fluc activity value of Fluc is 105.59, and the siN of 150nMpro-108、
The Fluc activity value of the cell of siP7-55, siNS5A-734 and siNS5B-1234 processing is respectively 103.08、104.40、104.08With
103.55, compared with siScr handles cell, Fluc activity reduces 332,15.8,32.45 and 113.2 times respectively.150nm simultaneously
SiNpro- 108, siP7-55, siNS5A-734 and siNS5B-1234 handle Shimen plants of titre difference of parental virus of cell
It is 101.09、102.38、101.87With 101.54TCID50/ mL drops respectively compared with the titre of the Shimen strain of siScr processing cell
870.9,44.3,111.3 and 313.3 times low, the result is consistent with the result of Fluc determination of activity, further confirms the present invention
The siRNA of offer has the potentiality for being applied to prepare swine fever virus resistant drug or reagent.
The present invention also provides the expression vectors of the siRNA containing the swine fever virus resistant infection activity；The expression carries
Any one of body in adenovirus vector, slow virus carrier, retrovirus vector or plasmid vector；Due to plasmid conduct
The duration of carrier, the validity delivered and in vivo effectiveness is not satisfactory；Though and slow virus and retrovirus vector
So the shRNA of external source can be persistently expressed, but will lead on gene integration to host chromosome；Adenovirus vector have efficiently,
The advantages that preparation purifying is simple, host range is wide and stability is good, therefore, the expression vector in the present invention are preferably that adenovirus carries
Body.
The present invention also provides the swine fever virus resistant siRNA in the drug or reagent of preparation prevention or treatment swine fever
Purposes.
The swine fever virus resistant siRNA that the present invention is filtered out is strong to CSFV interference or inhibitory activity, can be used for preparing prevention
Or the drug or reagent for the treatment of swine fever.
Invention further provides siRNA described in a kind of application to prevent or treat answering in swine fever virus infection
With, comprising: it will be in siRNA direct transfection to zooblast；Or by building SiRNA expression vector, single siRNA is connected
To expression vector, transfecting host；Corresponding siRNA is expressed in host, inhibits the duplication of swine fever virus or inhibits target base
The expression of cause has the function that prevention or treatment swine fever.
When the inhibitory effect of the siRNA of targeting one gene loci of CSFV genome is not significant, can also combine several
Gene loci uses, i.e., the multiple siRNA for targeting CSFV genome different genes is connected on expression vector, transfecting host；
Corresponding siRNA is expressed in host, can more preferably inhibit the duplication of swine fever virus or inhibits the expression of target gene, can be reached
To better prevention or the effect for the treatment of swine fever.
Technical solution of the present invention compared with prior art, has the advantages that
The present invention has successfully filtered out the N for targeting swine fever virus genome respectivelypro, 3 of NS5A and NS5B gene to pig
The interference of pestivirus or the strongest siRNA (siN of inhibitory activitypro- 108, siNS5A-239 and siNS5B-1234)；In addition, this
Invention makes public for the first time the swine fever virus resistant siRNA sequence of targeting swine fever virus genome NS5A gene and P7 gene；The present invention
Disclosed swine fever virus resistant siRNA is strong to the interference of swine fever virus or inhibitory activity, is used to prepare prevention or treats the medicine of swine fever
Object or reagent are, it can be achieved that effectively prevent swine fever.
The term definition involved in the present invention arrived
Unless otherwise defined, otherwise all technologies used herein and scientific term all have with it is of the art
Those of ordinary skill usually understands identical meaning.
Term " reverse genetics manipulation technology " means the infective molecule cloning by constructing RNA virus, in DNA molecular water
External manual operation is carried out to viral genome on flat, such as carries out point mutation, missing, insertion, transversion, indexing and complementation
The gene duplication and expression regulation mechanism, rna editing and spontaneous recombination and induction recombination, disease of RNA virus are studied in transformation with this
Interaction relationship, viral resistant strategies, gene therapy between poison and host are studied, and building novel viral vectors are outer to express
Source gene and the development etc. for carrying out vaccine.
Term " genome " means all DNA molecule in haploid cell including coded sequence and non-coding sequence
(fractionated viral is RNA).
Term " nucleotide sequence " means putting in order for base in DNA or RNA.
Term " virus titer " means that the virulence of virus or malicious valence, the unit for measuring virus titer have minimum lethal dose
(MLD), minimal infecting dose (MID) (MID), median lethal dose (LD50) and 50tissue infection dose (TCID50)。
Term " siRNA " means a kind of small RNA molecular (21-25 nucleotide), (in III family of RNase specifically by Dicer
Property identification double-stranded RNA enzyme) be process；SiRNA is the main constituents of siRISC, special as guidance during RNAi
" guide " of anisotropic dissection excites the silencing of target mRNA complementary to it.
Detailed description of the invention
Fig. 1 is CSFV-NproThe immunofluorescent test testing result of Fluc；
Fig. 2 is CSFV-NproThe dynamics of the Fluc gene expression of Fluc；
Fig. 3 is CSFV-NproFluc is used for the selection result of antiviral siRNA；*, p < 0.01；
Fig. 4 is CSFV-NproThe dose-response experiments result of Fluc siRNA antiviral for various concentration；*, p <
0.01；
Fig. 5 is siRNA to Shimen plants of parental virus of inhibitory effect verification result；*, p < 0.01.
Specific embodiment
The invention will now be further described with reference to specific embodiments, the advantages and features of the present invention will be with description and
It is apparent.It should be understood that described, examples are merely exemplary, does not constitute any restrictions to the scope of the present invention.This field
Technical staff should be understood that without departing from the spirit and scope of the invention can details to technical solution of the present invention and
Form is modified or is replaced, but these modifications or substitutions each fall within protection scope of the present invention.
1, experimental material
CSFV crossdrift (Shimen) strain (GenBank accession number AF092448.2) and PK-15 cell are by Scientia Agricultura Sinica
Harbin veterinary institute Vet Biotechnology National Key Laboratory, institute saves；SK6 cell is by Swedish National veterinary institute
Lihong doctor Liu give.
Plasmid pGEM-luc comprising Fluc gene is purchased from Promega company；Full-length infectious gram of Shimen plants of CSFV
Grand pBRCISM is constructed and is protected by Vet Biotechnology National Key Laboratory, Harbin Veterinary Medicine Inst., China Academy of Agriculture
It deposits.
For CSFV E2 albumen monoclonal antibody by Harbin Veterinary Medicine Inst., China Academy of Agriculture's veterinary biological skill
The preparation of art National Key Laboratory and preservation；The sheep anti-mouse igg of FITC label is purchased from Sigma company.Dual-Luciferase detection examination
Agent box is purchased from Promega company.
The design and screening of 1 swine fever virus resistant siRNA of embodiment
1, test method
1.1 carry the rescue of the swine fever recombinant virus of Fluc gene
Firefly luciferase gene is cloned into Shimen plants of overall length senses of swine fever virus by overlapping PCR method by the present invention
The N of metachromia clone pBRCISMpro(i.e. N between 412nd bit base and the 413rd bit base in code areaproThe 13rd, albumen and
Between 14 amino acids), the full-length infectious clone of the CSFV containing Fluc gene is constructed, pBRCISM-N is named asproFluc。
Utilize the reverse genetics manipulation technology pBRCISM-N based on rna plymerase iiproFluc saves out 5 plants of carryings
The recombination swine fever virus of Fluc gene, it may be assumed that CSFV-NproFluc、CSFV-NproFluc-1、CSFV-NproFluc-2、CSFV-
NproFluc-3 and CSFV-NproFluc-4, wherein recombinant virus CSFV-NproFluc is in the Fluc activity shown and loses
Other 4 plant weight group swine fever virus is substantially better than in terms of passing stability.
The present invention is by the most excellent swine fever recombinant virus CSFV-N of performanceproThe mechanism that Fluc submits patent to approve carries out
Preservation, microbial preservation number are as follows: CGMCC No.9058.
The indirect immunofluorescence assay (IFA) of 1.2 recombinant viruses
By the recombinant virus CSFV-N of rescueproFluc is inoculated in the SK6 cell for growing to 70%, and phosphate is used after 2h
Buffer solution (PBS) is washed 2 times and is changed to the fresh DMEM containing 4% fetal calf serum, in 5%CO2, continue to train in 37 DEG C of environment
It supports, carries out IFA test with anti-E2 monoclonal antibody after 48h, do negative control (NT) with non-infected cells.
Concrete operations are as follows: culture solution discarded, is cleaned cell 2 times with PBS, then fixes cell with cold dehydrated alcohol,
Anti- E2 monoclonal antibody is added after 30min, is washed cell 5 times after acting on 2h at room temperature with PBS, and it is diluted that 1:90 is added
The sheep anti-mouse igg of FITC label is protected from light effect 1h in room temperature, is washed cell 5 times with PBS, 5min/ times, aobvious being inverted fluorescence
Micro- microscopic observation is simultaneously taken pictures.
The uciferase activity of 1.3 recombinant viruses is analyzed
By SK6 cell inoculation in 24 porocyte culture plates, when cell grows to 80%, respectively with the recombination disease of rescue
Malicious CSFV-NproFluc and Shimen plants of parental virus infect SK6 cell by MOI=0.1 dosage, are placed in 5%CO2, 37 DEG C of rings
Continue to cultivate in border.After infection 12h, for 24 hours, 36h, 48h, 60h and 72h, cells and supernatant is discarded, and is washed with PBS
Cell 1 time, lysate is then added, 100 μ L lysates are added in every hole, and after cracking 15min on ice, cell pyrolysis liquid is added
In blank containing Luciferase Assay Reagent, it is immediately placed in fluorescence detector reading.
1.4RNA design and interference test
The present invention devises the siRNA molecule of 12 species specificity interference CSFV genomic coding sequence, targets N respectivelypro、
The coded sequence of P7, NS5A and NS5B gene, siRNA molecule nucleotide sequence are shown in Table 1.
RNA interference test carries out in 48 porocyte culture plates, by each siRNA molecule X-tremeGENE of 100nM
SiRNA disturbing molecule transfection reagent transfects the PK-15 cell for covering with 70% single layer respectively, is changed to after 6h thin containing 2% fetal calf serum
Born of the same parents DMEM, rear every hole meets 50TCID for 24 hours50Recombinant virus CSFV-NproFluc, and it is changed to the DMEM containing 4% fetal calf serum, 48h
Firefly luciferase activity value is measured afterwards.
1 interferential RNA molecular name of table and sequence
1.5CSFV-NproThe dose dependent of Fluc siRNA antiviral for various concentration is tested
In order to further verify various concentration siRNA to CSFV-NproThe inhibitory effect of Fluc, the present invention analyze targeting
The interference performance of four kinds of genes is by by force to 4 weak siRNA molecule (siNpro- 108, siP7-55, siNS5A-734 and
SiNS5B-1234) in the antiviral effect of various concentration.The specific method is as follows: by above-mentioned 4 kinds of siRNA molecule X-
TremeGENE siRNA transfection reagent is thin with the PK-15 that 70% single layer is covered in various concentration (50nM, 100nM and 150nM) transfection
In 48 porocyte culture plates of born of the same parents, each concentration repeats 3 holes, to be changed to after 6h containing 2% fetal calf serum DMEM, and rear every hole connects for 24 hours
50TCID50Recombinant virus CSFV-NproFluc, and it is changed to the DMEM containing 4% fetal calf serum, firefly luciferin is measured after 48h
Enzymatic activity value.Using the arithmetic mean of instantaneous value of 3 repetition test results as the hole firefly luciferase activity value.
1.6siRNA tests Shimen plants of parental virus of inhibitory effect
In order to further verify above-mentioned siRNA to Shimen plants of inhibitory effect, and compare based on recombinant virus and parent
The different screening techniques of two kinds of virus, the present invention analyze above-mentioned 4 siRNA molecule (siNpro-108、siNS5B-1234、
SiNS5A-734 and siP7-55) in various concentration to Shimen plants of antiviral effects.
Simultaneously the present invention using Shimen plant of CSFV parental virus have evaluated screening acquisition in the antiviral of various concentration
Effect.
The specific method is as follows: by above-mentioned 4 kinds of siRNA molecules with X-tremeGENE siRNA transfection reagent with various concentration
In 48 porocyte culture plates of the PK-15 cell that 70% single layer is covered in (50nM, 100nM and 150nM) transfection, each concentration is repeated
3 holes are changed to containing 2% fetal calf serum DMEM after 6h, for 24 hours after every hole meet 50TCID50Shimen plants of parental virus, and be changed to and contain
Multigelation cell receives poison after the DMEM of 4% fetal calf serum, 48h, the titre of every hole virus is measured with IFA, according to Reed-M ü
Nch formula calculates, using the arithmetic mean of instantaneous value of 3 repetition test results as the titre of hole virus.
1.7 statistical analysis
Statistical analysis is carried out to all data using SAS statistics software, compares the difference between each group.Wherein *, p <
0.05；*, p < 0.01；* *, p < 0.001.
2, test result
The indirect immunofluorescence assay result of 2.1 recombinant viruses
Indirect immunofluorescence assay confirmation, recombinant virus CSFV-NproFluc can be identified (figure by swine fever virus E2 antibody
1)。
The uciferase activity of 2.2 recombinant viruses analyzes result
Recombinant virus CSFV-N is used respectivelyproFluc and Shimen plants of parental virus are thin by MOI=0.1 dosage infection SK6
Born of the same parents, and after infection 12h, for 24 hours, 36h, 48h, 60h and 72h measurement Fluc activity.
The result shows that 12h, CSFV-N after infectionproThe Fluc activity of Fluc is about the 15 of Shimen plants of infection cells
Times, and 60h after infection, Fluc activity reach peak value, the 5 × 10 of about Shimen plants of infection cell6Again (Fig. 2).
2.3RNA interference test result
The present invention is directed to Npro, P7, NS5A and NS5B gene 12 CSFV specific siRNAs detected.As a result table
Bright, when disturbing molecule concentration is 100nM, Fluc activity is reduced, especially siNpro- 108 (p=0.0011), siNS5A-239
(p=0.0032) and the cell of siNS5B-1234 (p=0.0054) processing, Fluc activity are remarkably decreased (Fig. 3).RNA interference examination
Test the result shows that, these siRNA, which have, prepares the potentiality of swine fever virus resistant drug or reagent.
2.4CSFV-NproThe dose-response experiments result of Fluc siRNA antiviral for various concentration
Test result shows 4 kinds of siRNA (siNpro- 108, siP7-55, siNS5A-734 and siNS5B-1234) not
Same concentration (50nM, 100nM and 150nM) is to CSFV-NproFluc virus has significant inhibiting effect (Fig. 4).For 150nM
SiScr processing cell, CSFV-NproThe Fluc activity value of Fluc is 105.59, and the siN of 150nMpro-108、siP7-55、
The Fluc activity value of the cell of siNS5A-734 and siNS5B-1234 processing is respectively 103.08、104.40、104.08With 103.55, with
SiScr processing cell is compared, and Fluc activity reduces 332,15.8,32.45 and 113.2 times respectively.
2.5siRNA is to Shimen plants of parental virus of inhibitory effect
The present invention analyzes the siRNAs (siN of 4 kinds of genespro- 108, siP7-55, siNS5A-734 and siNS5B-
1234) in various concentration (50,100 and 150nM) to Shimen plants of parental virus of antiviral effect.The result shows that 4 kinds
SiRNA has significant inhibiting effect (Fig. 5) to Shimen plants of parental virus in 50nM, 100nM and 150nM various concentration.It is right
In the siScr of 150nM, Shimen plants of titres of parental virus reach 104TCID50/ mL, with the cell that is handled without siRNA
Shimen plants of titres (about 104.44TCID50/ mL) it is similar, and the siN of 150nMpro- 108, siP7-55, siNS5A-734 and
The Shimen strain titre of the cell of siNS5B-1234 processing is respectively 101.09、102.38、101.87With 101.54TCID50/ mL, with
The titre of the Shimen strain of siScr processing cell is compared, and reduces 870.9,44.3,111.3 and 313.3 times (Fig. 5) respectively.With
Upper result is consistent with the result of Fluc determination of activity, further confirms that these siRNA have and prepares swine fever virus resistant drug or examination
The potentiality of agent.
Claims (4)
1. targeting the siRNA with swine fever virus resistant infection activity of swine fever virus NS5A gene, it is characterised in that: its nucleotide
Sequence is shown in SEQ ID NO.7.
2. the expression vector containing the siRNA described in claim 1 with swine fever virus resistant infection activity, it is characterised in that: institute
State any one of expression vector in adenovirus vector, slow virus carrier or plasmid vector.
3. expression vector according to claim 2, which is characterized in that the expression vector is adenovirus vector.
4. the siRNA described in claim 1 with swine fever virus resistant infection activity is in preparation prevention or the drug for the treatment of swine fever
Or the application in reagent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610121446.9A CN105671046B (en) | 2014-06-09 | 2014-06-09 | The siRNA of swine fever virus resistant infection and its application |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610121446.9A CN105671046B (en) | 2014-06-09 | 2014-06-09 | The siRNA of swine fever virus resistant infection and its application |
| CN201410252667.0A CN104059914B (en) | 2014-06-09 | 2014-06-09 | The siRNA that swine fever virus resistant infects and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410252667.0A Division CN104059914B (en) | 2014-06-09 | 2014-06-09 | The siRNA that swine fever virus resistant infects and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105671046A CN105671046A (en) | 2016-06-15 |
| CN105671046B true CN105671046B (en) | 2019-03-01 |
Family
ID=56307838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610121446.9A Expired - Fee Related CN105671046B (en) | 2014-06-09 | 2014-06-09 | The siRNA of swine fever virus resistant infection and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105671046B (en) |
-
2014
- 2014-06-09 CN CN201610121446.9A patent/CN105671046B/en not_active Expired - Fee Related
Non-Patent Citations (5)
| Title |
|---|
| In vitro inhibition of classical swine fever virus replication by siRNAs targeting Npro and NS5B genes;Xingran Xu et al.;《Antiviral Research》;20081231;第78卷;全文 * |
| KC503764.1;Genbank;《Genbank》;20140411;全文 * |
| 干扰RNA抑制猪瘟病毒增殖效果研究;徐兴然;《中国博士学位论文全文数据库（电子期刊）农业科技辑年期2005/06页码D050-14》;20050615;表3-1 * |
| 徐兴然 等.特异性siRNA抑制猪瘟病毒的增殖.《中国畜牧兽医学会2004学术年会暨第五届全国畜牧兽医青年科技工作者学术研讨会论文集（下册）》.2004, * |
| 特异性siRNA抑制猪瘟病毒的增殖;徐兴然 等;《中国畜牧兽医学会2004学术年会暨第五届全国畜牧兽医青年科技工作者学术研讨会论文集（下册）》;20040930;摘要，1.2方法部分，2.1/2.4部分 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105671046A (en) | 2016-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ye et al. | Zoonotic origins of human coronaviruses | |
| Lee et al. | Mechanism of virulence attenuation of glycosaminoglycan-binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus | |
| Lee et al. | Common E protein determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and West Nile viruses | |
| Nagai et al. | Phylogenetic analysis of bovine viral diarrhea viruses using five different genetic regions | |
| Battilani et al. | Virulent feline calicivirus disease in a shelter in Italy: a case description | |
| CN110592172B (en) | Method and target for screening JEV resistance gene by using CRISPR/Cas9 knockout library technology | |
| CN107815441A (en) | A kind of II type Pseudorabies virus attenuated strain and its preparation method and application | |
| CN110101705A (en) | The anti-viral uses of BET family protein inhibitor | |
| Jóźwik et al. | Vaccination against porcine parvovirus protects against disease, but does not prevent infection and virus shedding after challenge infection with a heterologous virus strain | |
| Li et al. | A QP509L/QP383R-deleted African swine fever virus is highly attenuated in swine but does not confer protection against parental virus challenge | |
| Magalhaes et al. | Induction of RNA interference to block Zika virus replication and transmission in the mosquito Aedes aegypti | |
| Sun et al. | A SARS-CoV-2 variant with the 12-bp deletion at E gene | |
| CN105274142B (en) | 55 type adenovirus vector of science recombined human and its preparation method and application | |
| Li et al. | Efficient and stable rescue of classical swine fever virus from cloned cDNA using an RNA polymerase II system | |
| Sakoda et al. | Development and evaluation of indirect enzyme-linked immunosorbent assay for a screening test to detect antibodies against classical swine fever virus | |
| Tang et al. | Application of siRNA against SARS in the rhesus macaque model | |
| Wu et al. | Identification of two amino acids within E2 important for the pathogenicity of chimeric classical swine fever virus | |
| Wu et al. | The first nonmammalian pegivirus demonstrates efficient in vitro replication and high lymphotropism | |
| CN105853998B (en) | Osteopetrosis correlation transmembrane protein is treating or preventing the application in EV71 infection medicine | |
| Khatoon et al. | Cytokine responses in pigs after natural infection with classical swine fever virus. | |
| CN104017779B (en) | Express Recombinant Swine pestivirus and the application thereof of firefly luciferase gene | |
| Desai et al. | 5′-UTR-based phylogenetic analysis of classical swine fever virus isolates from India | |
| Yang et al. | Biophysical characterization of Japanese encephalitis virus (KV1899) isolated from pigs in Korea | |
| Tao et al. | Attenuated porcine-derived type 2 bovine viral diarrhea virus as vector stably expressing viral gene | |
| CN105671046B (en) | The siRNA of swine fever virus resistant infection and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190301 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |